Oral GLP-1
Jun 15, 2026
The Oral GLP-1 Revolution: How Pill-Based Drugs Are Reshaping the Obesity Treatment Space
Summary The obesity drug landscape is shifting from injectable GLP-1s to oral pill-based treatments, marking a major turning point in pharmacotherapy. Two oral GLP-1s have now received FDA approval: Novo Nordisk's WEGOVY pill (December 2025) and Eli Lilly's FOUNDAYO (April 2026). Several companies, such a...
Read More...
-Agonist.png "Toll-like Receptors Agonist")
